

NATTOPHARMA AWARDED GRANT FROM NORWEGIAN RESEARCH COUNCIL

OSLO, NORWAY (02 JULY 2020) – The Norwegian Research Council has awarded a grant estimated to be NOK 15 million to NattoPharma ASA (“NattoPharma”) to help fund a multi-year project to develop new vitamin formulations. The project will utilize NattoPharma’s MenaQ7[®] Vitamin K2 as MK -7 and the research part will be conducted together with SINTEF AS, Department of Biotechnology and Nanomedicine (“SINTEF”).

The collaboration between SINTEF and NattoPharma aims to develop new and smart technologies for vitamin formulations, building on NattoPharma’s former successes of developing globally competitive and clinically validated products mixed with SINTEF’s strong background in research within the area of biotechnology and nanomedicine.

“The development of new technologies and the planned innovations in the project will contribute to further development and growth of the national vitamin industry”, says Håvard Sletta, Research manager at the Department of Biotechnology and Nanomedicine at SINTEF.

“We are very excited to receive this grant as it will help us realize a research project that will continue to build on our strong position as market leader in the vitamin K2 world. By executing this project, we expect to take the next step in the development of vitamin formulations and secure our continued leading position in the industry”, says Kjetil Ramsøy, Chief Executive Officer of NattoPharma.

For more information, please contact:

Robert Schrama, CFO
E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities